美股异动丨诺和诺德盘前跌近5%，预计2026年销售额和营业利润下降

Group 1 - The core viewpoint of the news is that Novo Nordisk's stock has experienced significant declines following disappointing sales forecasts, with a projected annual sales decline for the first time in nine years [1] - In Q4, Novo Nordisk's sales decreased by 7.6% year-on-year, although this was better than analyst expectations, and sales of the weight loss drug Wegovy also exceeded forecasts [1] - The company anticipates a sales and operating profit decline of 5%-13% by 2026, while analysts predict declines of 1.4% and 3.1% respectively [1] Group 2 - The CEO of Novo Nordisk indicated that the company will face "unprecedented pricing pressure" by 2026 [1] - The global GLP-1 market is expected to continue expanding, which may allow the company to increase sales volume, although at lower actual prices [1] - Following the forecast of declining sales and profits, traders expect Novo Nordisk's stock to drop by 13%-15% [1]